For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Clinical rehabilitation guideline for people with Long COVID in Aotearoa New Zealand
Clinical rehabilitation guideline for people with Long COVID in Aotearoa New Zealand

Clinical Rehabilitation Guideline for People with Long COVID in Aotearoa New Zealand
This guideline is intended to provide clinical guidance on long COVID conditions in both children and adults in Aotearoa New Zealand.
The guideline is an evidence-based summary that covers the definition and diagnosis of long COVID.
It seeks to provide the best evidence currently available to assist informed decision-making to improve the health, vocational and social outcomes for individuals with long COVID.
The guideline is intended for use by primary care practitioners, community and hospital clinicians, policy makers, funders, parents, carers, specialists, individuals with long COVID, whānau and any others who make provision for individuals with long COVID.
The factsheets have a summary of the resources available for individuals and clinicians.
The symptom map is a tool which has been created to assist with clinical assessment of individuals presenting with long COVID symptom.
The guideline can be accessed here